Contrasting BioNexus Gene Lab (NASDAQ:BGLC) and QXO (NYSE:QXO)

QXO (NYSE:QXO) and BioNexus Gene Lab (NASDAQ:BGLC) are both industrials companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.

Analyst Ratings

This is a breakdown of recent recommendations for QXO and BioNexus Gene Lab, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
QXO	1	1	15	1	2.89
BioNexus Gene Lab	1	0	0	0	1.00

QXO presently has a consensus target price of $25.21, suggesting a potential upside of 144.21%. Given QXO’s stronger consensus rating and higher probable upside, equities research analysts plainly believe QXO is more favorable than BioNexus Gene Lab.

Institutional and Insider Ownership

58.7% of QXO shares are owned by institutional investors. Comparatively, 18.9% of BioNexus Gene Lab shares are owned by institutional investors. 41.0% of QXO shares are owned by insiders. Comparatively, 0.1% of BioNexus Gene Lab shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

QXO has a beta of 2.3, suggesting that its share price is 130% more volatile than the S&P 500. Comparatively, BioNexus Gene Lab has a beta of 4.22, suggesting that its share price is 322% more volatile than the S&P 500.

Earnings & Valuation

This table compares QXO and BioNexus Gene Lab”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
QXO	$6.84 billion	1.57	-$279.40 million	($0.90)	-11.47
BioNexus Gene Lab	$7.43 million	0.50	-$2.98 million	($1.26)	-1.00

BioNexus Gene Lab has lower revenue, but higher earnings than QXO. QXO is trading at a lower price-to-earnings ratio than BioNexus Gene Lab, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares QXO and BioNexus Gene Lab’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
QXO	-5.17%	2.41%	1.20%
BioNexus Gene Lab	-82.38%	-32.92%	-29.75%

Summary

QXO beats BioNexus Gene Lab on 12 of the 15 factors compared between the two stocks.

About QXO

QXO, Inc. operates as a business application, technology, and consulting company in North America. The company provides solutions for accounting and business management, financial reporting, enterprise resource planning, human capital management, warehouse management systems, customer relationship management, and business intelligence. It also offers value-added services that focuses on consulting and professional, specialized programming, training, and technical support services. In addition, the company provides information technology managed services, such as cybersecurity, application hosting, disaster recovery, business continuity, cloud, and other services; and data back-up, network maintenance, and upgrade services. It serves small and medium-sized businesses primarily in the manufacturing, distribution, and service industries. QXO, Inc. is headquartered in Greenwich, Connecticut.

About BioNexus Gene Lab

BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.